Concluded Case

UPDATE ON CV OUTCOMES AND HF WITH ERTUGLIFLOZIN, SGLT2 INHIBITOR.

Dear my friends and fellow Colleagues, Here is an update on Ertugliflozin, SGLT2 Inhibitor, from E Merck on CV outcomes and HHF. SGLT 2 inhibitor Ertugliflozin fails to prove superiority over placebo in reducing combined incidence of CV death or Heart Failure hospitalisation in T2DM patients with Established CV Disease, April, 2020. This molecule is approved by USFDA. But not yet available in India. Regards and thanks, Dr Sepuri Krishna Mohan.

4 Likes

LikeAnswersShare
Concluded answer
Informative updates -very helpful.not to be used in comorbid condition of cvs as priority.
All Answers
Thanx for update Uptill now none ther than dapa cana or remogliflozine are useful even amongst these three dapa stands tall
Thanx dr Dinesh Gupta
0

View 1 other reply

Informative updates -very helpful.not to be used in comorbid condition of cvs as priority.
Valuable opinion
0
NICE UPDATE.... USEFUL AND HELPFUL
Valuable opinion
0

Cases that would interest you